Tebao Biotech announced that the company plans to use its own capital of 100 million yuan as a limited partner to subscribe for shares of the Tianjin Lisi Xingshen Equity Investment Partnership. This investment is a financial investment. Company director Lan Berlin plans to invest 200 million yuan as the fund's limited partner. This transaction constitutes a related transaction and does not constitute a major asset restructuring. The fund targets a total pledged investment of not less than 3 billion yuan. The investment target is unlisted companies in the early to medium term in the field of artificial intelligence. Currently, the relevant agreement has not been signed, and the fund still needs to complete procedures such as registration of industrial and commercial changes in the future, and there is uncertainty about implementation.

Tebao Biotech announced that the company plans to use its own capital of 100 million yuan as a limited partner to subscribe for shares of the Tianjin Lisi Xingshen Equity Investment Partnership. This investment is a financial investment. Company director Lan Berlin plans to invest 200 million yuan as the fund's limited partner. This transaction constitutes a related transaction and does not constitute a major asset restructuring. The fund targets a total pledged investment of not less than 3 billion yuan. The investment target is unlisted companies in the early to medium term in the field of artificial intelligence. Currently, the relevant agreement has not been signed, and the fund still needs to complete procedures such as registration of industrial and commercial changes in the future, and there is uncertainty about implementation.